Azurin Peptide Stabilizes P53 to Prevent Premalignant Lesions

The patent applies local quality by modifying the chemopreventive agent to exhibit different properties in different cellular environments. The agent is designed to be activated or become effective specifically within cancer cells through mechanisms such as selective uptake, intracellular processing, or pH-dependent activation, thereby exerting its chemopreventive effect locally at the cancer cell site while remaining inactive or less active in normal cells.

The patent utilizes parameter changes by altering the chemical, physical, or biological parameters of the chemopreventive agent to achieve selective cancer cell targeting. This may involve changing the agent's solubility, charge, size, or molecular structure to exploit differences between cancer and normal cells, such as enhanced permeability and retention effect in tumors or differential expression of transporters, thereby improving selectivity without harming normal cells.

The patent applies self-service by designing chemopreventive agents that automatically achieve selective cancer cell targeting through their inherent properties without requiring complex external control systems. The agents may self-assemble, self-activate, or self-target cancer cells based on their molecular characteristics and the biological differences between cancer and normal cells, thereby achieving high selectivity while minimizing therapeutic complexity.

The patent utilizes intermediaries by employing carrier molecules, targeting ligands, or delivery vehicles that mediate the selective delivery of chemopreventive agents to cancer cells. These intermediaries facilitate selective uptake or binding to cancer cells through specific interactions such as receptor-ligand binding or antibody-antigen recognition, thereby achieving high selectivity while the intermediary itself manages the complexity of the targeting mechanism.